CCL2 and ovarian cancer: On the pro-tumor side, CCL2 (MCP-1), a potent monocyte chemoattractant (33), is correlated with poor overall survival (34) and contributes to ovarian cancer progression through recruitment of M2 macrophages (35), promotion of tumor metastasis (36), and promotion of chemotherapy resistance (34).